Financhill
Sell
20

DYN Quote, Financials, Valuation and Earnings

Last price:
$23.91
Seasonality move :
12.85%
Day range:
$23.65 - $24.90
52-week range:
$12.06 - $47.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.46x
Volume:
1.5M
Avg. volume:
1M
1-year change:
104.87%
Market cap:
$2.4B
Revenue:
--
EPS (TTM):
-$3.56

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
DYN
Dyne Therapeutics
-- -$0.71 -- -21.38% --
CPRX
Catalyst Pharmaceuticals
$123.4M $0.51 20.93% 70.76% --
RGNX
Regenxbio
$24.4M -$1.10 5.56% -21.21% $37.64
RNA
Avidity Biosciences
$4.6M -$0.72 27.88% -6.56% $68.27
SRPT
Sarepta Therapeutics
$405.1M $0.37 46.71% 126.15% $185.10
VRTX
Vertex Pharmaceuticals
$2.7B $4.13 10.59% 10.32% $498.37
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
DYN
Dyne Therapeutics
$23.99 -- $2.4B -- $0.00 0% --
CPRX
Catalyst Pharmaceuticals
$21.27 -- $2.5B 18.03x $0.00 0% 5.63x
RGNX
Regenxbio
$7.63 $37.64 $378M -- $0.00 0% 4.32x
RNA
Avidity Biosciences
$31.82 $68.27 $3.8B -- $0.00 0% 309.49x
SRPT
Sarepta Therapeutics
$118.97 $185.10 $11.4B 77.25x $0.00 0% 7.30x
VRTX
Vertex Pharmaceuticals
$397.27 $498.37 $102.3B 25.59x $0.00 0% 9.73x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
DYN
Dyne Therapeutics
-- 3.180 -- --
CPRX
Catalyst Pharmaceuticals
-- 0.945 -- 4.75x
RGNX
Regenxbio
-- 4.247 -- 2.73x
RNA
Avidity Biosciences
-- 3.500 -- 17.60x
SRPT
Sarepta Therapeutics
50.13% 1.327 10.29% 2.45x
VRTX
Vertex Pharmaceuticals
-- 0.893 -- 2.08x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
DYN
Dyne Therapeutics
-- -$105.7M -- -- -- -$74.9M
CPRX
Catalyst Pharmaceuticals
$109.4M $50.9M 27.81% 27.81% 39.56% $72.6M
RGNX
Regenxbio
$11.8M -$62.1M -69.62% -69.62% -242.91% -$40.9M
RNA
Avidity Biosciences
-- -$98.1M -30.66% -30.66% -4200.94% -$67.3M
SRPT
Sarepta Therapeutics
$375.5M $22.2M 5.51% 12.48% 8.33% -$108M
VRTX
Vertex Pharmaceuticals
$2.4B $1.1B -2.89% -2.89% 44.43% $1.3B

Dyne Therapeutics vs. Competitors

  • Which has Higher Returns DYN or CPRX?

    Catalyst Pharmaceuticals has a net margin of -- compared to Dyne Therapeutics's net margin of 34.1%. Dyne Therapeutics's return on equity of -- beat Catalyst Pharmaceuticals's return on equity of 27.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    DYN
    Dyne Therapeutics
    -- -$0.96 --
    CPRX
    Catalyst Pharmaceuticals
    85.02% $0.35 $660.9M
  • What do Analysts Say About DYN or CPRX?

    Dyne Therapeutics has a consensus price target of --, signalling upside risk potential of 110.16%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 51.62%. Given that Dyne Therapeutics has higher upside potential than Catalyst Pharmaceuticals, analysts believe Dyne Therapeutics is more attractive than Catalyst Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    DYN
    Dyne Therapeutics
    0 0 0
    CPRX
    Catalyst Pharmaceuticals
    0 0 0
  • Is DYN or CPRX More Risky?

    Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.748, suggesting its less volatile than the S&P 500 by 25.213%.

  • Which is a Better Dividend Stock DYN or CPRX?

    Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DYN or CPRX?

    Dyne Therapeutics quarterly revenues are --, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $128.7M. Dyne Therapeutics's net income of -$97.1M is lower than Catalyst Pharmaceuticals's net income of $43.9M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 18.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 5.63x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DYN
    Dyne Therapeutics
    -- -- -- -$97.1M
    CPRX
    Catalyst Pharmaceuticals
    5.63x 18.03x $128.7M $43.9M
  • Which has Higher Returns DYN or RGNX?

    Regenxbio has a net margin of -- compared to Dyne Therapeutics's net margin of -246.3%. Dyne Therapeutics's return on equity of -- beat Regenxbio's return on equity of -69.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    DYN
    Dyne Therapeutics
    -- -$0.96 --
    RGNX
    Regenxbio
    48.81% -$1.17 $301.4M
  • What do Analysts Say About DYN or RGNX?

    Dyne Therapeutics has a consensus price target of --, signalling upside risk potential of 110.16%. On the other hand Regenxbio has an analysts' consensus of $37.64 which suggests that it could grow by 393.27%. Given that Regenxbio has higher upside potential than Dyne Therapeutics, analysts believe Regenxbio is more attractive than Dyne Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    DYN
    Dyne Therapeutics
    0 0 0
    RGNX
    Regenxbio
    6 0 0
  • Is DYN or RGNX More Risky?

    Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.243, suggesting its more volatile than the S&P 500 by 24.251%.

  • Which is a Better Dividend Stock DYN or RGNX?

    Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DYN or RGNX?

    Dyne Therapeutics quarterly revenues are --, which are smaller than Regenxbio quarterly revenues of $24.2M. Dyne Therapeutics's net income of -$97.1M is lower than Regenxbio's net income of -$59.6M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 4.32x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DYN
    Dyne Therapeutics
    -- -- -- -$97.1M
    RGNX
    Regenxbio
    4.32x -- $24.2M -$59.6M
  • Which has Higher Returns DYN or RNA?

    Avidity Biosciences has a net margin of -- compared to Dyne Therapeutics's net margin of -3441.7%. Dyne Therapeutics's return on equity of -- beat Avidity Biosciences's return on equity of -30.66%.

    Company Gross Margin Earnings Per Share Invested Capital
    DYN
    Dyne Therapeutics
    -- -$0.96 --
    RNA
    Avidity Biosciences
    -- -$0.65 $1.5B
  • What do Analysts Say About DYN or RNA?

    Dyne Therapeutics has a consensus price target of --, signalling upside risk potential of 110.16%. On the other hand Avidity Biosciences has an analysts' consensus of $68.27 which suggests that it could grow by 114.56%. Given that Avidity Biosciences has higher upside potential than Dyne Therapeutics, analysts believe Avidity Biosciences is more attractive than Dyne Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    DYN
    Dyne Therapeutics
    0 0 0
    RNA
    Avidity Biosciences
    7 0 0
  • Is DYN or RNA More Risky?

    Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Avidity Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock DYN or RNA?

    Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avidity Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Avidity Biosciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DYN or RNA?

    Dyne Therapeutics quarterly revenues are --, which are smaller than Avidity Biosciences quarterly revenues of $2.3M. Dyne Therapeutics's net income of -$97.1M is lower than Avidity Biosciences's net income of -$80.4M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Avidity Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 309.49x for Avidity Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DYN
    Dyne Therapeutics
    -- -- -- -$97.1M
    RNA
    Avidity Biosciences
    309.49x -- $2.3M -$80.4M
  • Which has Higher Returns DYN or SRPT?

    Sarepta Therapeutics has a net margin of -- compared to Dyne Therapeutics's net margin of 7.2%. Dyne Therapeutics's return on equity of -- beat Sarepta Therapeutics's return on equity of 12.48%.

    Company Gross Margin Earnings Per Share Invested Capital
    DYN
    Dyne Therapeutics
    -- -$0.96 --
    SRPT
    Sarepta Therapeutics
    80.37% $0.34 $2.4B
  • What do Analysts Say About DYN or SRPT?

    Dyne Therapeutics has a consensus price target of --, signalling upside risk potential of 110.16%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 55.59%. Given that Dyne Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Dyne Therapeutics is more attractive than Sarepta Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    DYN
    Dyne Therapeutics
    0 0 0
    SRPT
    Sarepta Therapeutics
    12 0 1
  • Is DYN or SRPT More Risky?

    Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

  • Which is a Better Dividend Stock DYN or SRPT?

    Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DYN or SRPT?

    Dyne Therapeutics quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Dyne Therapeutics's net income of -$97.1M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 77.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 7.30x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DYN
    Dyne Therapeutics
    -- -- -- -$97.1M
    SRPT
    Sarepta Therapeutics
    7.30x 77.25x $467.2M $33.6M
  • Which has Higher Returns DYN or VRTX?

    Vertex Pharmaceuticals has a net margin of -- compared to Dyne Therapeutics's net margin of 37.71%. Dyne Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

    Company Gross Margin Earnings Per Share Invested Capital
    DYN
    Dyne Therapeutics
    -- -$0.96 --
    VRTX
    Vertex Pharmaceuticals
    85.84% $4.01 $15.6B
  • What do Analysts Say About DYN or VRTX?

    Dyne Therapeutics has a consensus price target of --, signalling upside risk potential of 110.16%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.37 which suggests that it could grow by 25.42%. Given that Dyne Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Dyne Therapeutics is more attractive than Vertex Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    DYN
    Dyne Therapeutics
    0 0 0
    VRTX
    Vertex Pharmaceuticals
    17 12 2
  • Is DYN or VRTX More Risky?

    Dyne Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

  • Which is a Better Dividend Stock DYN or VRTX?

    Dyne Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DYN or VRTX?

    Dyne Therapeutics quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Dyne Therapeutics's net income of -$97.1M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Dyne Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics is -- versus 9.73x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DYN
    Dyne Therapeutics
    -- -- -- -$97.1M
    VRTX
    Vertex Pharmaceuticals
    9.73x 25.59x $2.8B $1B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 3.65% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 4.9% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 4.4% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock